

## **IMAGION BIOSYSTEMS LIMITED**

**ASX: IBX** 

15 January 2024

# **Imagion Announces CEO Departure**

MELBOURNE – Imagion Biosystems (ASX:IBX), a company dedicated to improving healthcare through the early detection of cancer, wishes to inform the market that CEO Isaac Bright, MD has resigned to pursue other opportunities effective January 15<sup>th</sup>, 2024. Chairman Bob Proulx will resume operating responsibilities as interim Executive Chair. Mr. Proulx will resume Executive Chair responsibilities with no additional remuneration other than directors fees until further notice.

--- ENDS ---

## **About Imagion Biosystems**

Established in 2017 and headquartered in the San Diego, California, US, Imagion Biosystems is an ASX-listed company dedicated to developing innovative medical imaging technologies for various cancer types. Imagion Biosystems is advancing clinical development of its MagSense® platform technology to revolutionize cancer diagnosis, introducing molecular imaging to MRI. The Company's lead program has demonstrated its innovative technology embodied in MagSense® HER2 Imaging Agent (MSH2IA) is safe and well-tolerated in patients diagnosed with HER2+ breast cancer. Imagion Biosystems' MagSense® pipeline includes prostate cancer, ovarian cancer, pancreatic cancer, and brain cancer programs.

For more information, visit https://imagionbiosystems.com/investor-hub/

#### **Imagion Biosystems Interactive Investor Hub**

Engage with us directly by asking questions, watching video summaries, and seeing what other shareholders have to say about this and past announcements at our Investor Hub: https://investorhub.imagionbiosystems.com/

## **Authorisation & Additional information**

This announcement was authorised by the Disclosure Committee of Imagion Biosystems Limited.

## **Australian Media & Investor Relations:**

Geoff Hollis, CFO and Company Secretary geoff.hollis@imagionbio.com +61 438 168 008

## **U.S. Media Contact**

Casie Ost casie.ost@imagionbio.com +1-619-693-4428

